Menu Search
Equities

CANbridge Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1228:HKG

CANbridge Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)2.79
  • Today's Change0.05 / 1.82%
  • Shares traded157.00k
  • 1 Year change+1,424.59%
  • Beta--
Data delayed at least 15 minutes, as of Mar 05 2026 03:18 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company. It is focused on research, development and commercialization of transformative therapies for rare disease. It has a drug portfolio, with three approved drugs and a pipeline of eight assets, targeting rare disease indications that have unmet needs. These include Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria and other complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases. Its pipeline includes Hunterase, Livmarli, CAN106, and CAN103. Hunterase is an enzyme replacement therapy for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. Livmarli an oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter that is under development to treat rare cholestatic liver diseases including Alagille syndrome and progressive familial intrahepatic cholestasis.

  • Revenue in USD (TTM)9.07m
  • Net income in USD-19.73m
  • Incorporated2017
  • Employees45.00
  • Location
    CANbridge Pharmaceuticals Inc139 Main Street 1St FloorCAMBRIDGE 02142United StatesUSA
More ▼

Institutional shareholders

8.25%Per cent of shares held by top holders
HolderShares% Held
Athos Capital Ltd.as of 30 Jun 202542.15m8.25%
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.